Successful pregnancy after cladribine therapy for hairy cell leukemia.
Hairy cell leukemia (HCL) is predominantly seen in men with a median age of 52, and often treated with 2-chlorodeoxyadenosine (cladribine, 2-CdA). Perhaps as a result of the demographics of HCL, studies of ovarian function after such therapy are lacking, even though cladribine can induce DNA strand breaks. In this report, the first case of a patient diagnosed with HCL who then went on to a successful pregnancy is described, suggesting that fertility may be preserved in at least some female patients treated with this agent.
Orlowski
Robert Z
RZ
The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295, USA. R_Orlowski@med.unc.edu
D000328:Adult; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D011247:Pregnancy / Q000502:physiology*; D013997:Time Factors
D017338:Cladribine